
The Pharmacare News Bulletins, which are mailed to pharmacies and prescribers, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.
Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.
April Bulletin Vol 25-07 (PDF)
New Exception Status Product: Osnuvo (teriparatide); Criteria Updates: Bimzelx (bimekizumab), Imbruvica (ibrutinib), Tagrisso (osimertinib), Venclexta (venetoclax), Cipro (ciprofloxacin and generics), Levaquin (levofloxacin and generics), Avelox (moxifloxacin and generics), Norfloxacin; Change in Benefit Status; New Benefits
March Bulletin Vol 25-06 (PDF)
Infliximab IV IV (Inflectra) Changes and New Infliximab IV Products
,New Exception Status Products; Sohonos (palovarotene); Ticagrelor (Brilinta and
generic brands); Truqap (capivasertib) Change in Benefit Status
New Benefits
March Bulletin Vol 25-05 (PDF)
Infliximab IV (Inflectra) Changes Changes for Submission of Claims over $9,999.99.
March Bulletin Vol 25-04 (PDF)
Pharmacists' Administration of Respiratory Syncytial Virus (RSV) Vaccine in Long-term Care Facilities and Residential Care Facilities
February Bulletin Vol 25-03 (PDF)
New Exception Status Benefits: Koselugo (selumetinib), Remsima SC (infliximab), Welireg (belzutifan); Criteria Update: Kerendia (finerenone); Coverage Period Updates for Biologics and Janus Kinase (JAK) Inhibitors.
February Bulletin Vol 25-02 (PDF)
Nova Scotia Formulary Updates, Physician Assistant and Podiatrist Prescribing
January Bulletin Vol 25-01 (PDF)
New Exception Status Products: Amvuttra (vutrisiran), Orladeyo (berotralstat hydrochloride) Criteria Update, Verzenio (abemaciclib) New Benefits Generic Drug Pricing Reminder Auditor’s Corner
April Bulletin Vol 25-04 (PDF)
New Exception Status Product: Osnuvo (teriparatide); Criteria Updates: Bimzelx (bimekizumab), Imbruvica (ibrutinib), Tagrisso (osimertinib), Venclexta (venetoclax), Cipro (ciprofloxacin and generics), Levaquin (levofloxacin and generics), Avelox (moxifloxacin and generics), Norfloxacin; Change in Benefit Status; New Benefits
March Bulletin Vol 25-03 (PDF)
Infliximab IV (Inflectra) Changes
and New Infliximab IV Products;
New Exception Status Products
Sohonos (palovarotene),
Ticagrelor (Brilinta and generic brands),
Truqap (capivasertib);
Change in Benefit Status,
New Benefits
February Bulletin Vol 25-02 (PDF)
New Exception Status Benefits: Koselugo (selumetinib), Remsima SC (infliximab), Welireg (belzutifan); Criteria Update: Kerendia (finerenone); Coverage Period Updates for Biologics and Janus Kinase (JAK) Inhibitors.
January Bulletin Vol 25-01 (PDF)
New Exception Status Products: Amvuttra (vutrisiran), Orladeyo (berotralstat hydrochloride) Criteria Update, Verzenio (abemaciclib) New Benefits
Complete Volume Twenty Four 2024 (PDF)
Complete Volume Twenty Three 2023 (PDF)
Complete Volume Twenty Two 2022 (PDF)
Complete Volume Twenty One 2021 (PDF)
Complete Volume Twenty 2020 (PDF)
Complete Volume Nineteen 2019 (PDF)
Complete Volume Eighteen 2018 (PDF)
Complete Volume Seventeen 2017 (PDF)
Complete Volume Twenty Four 2024 (PDF)
Complete Volume Twenty Three 2023 (PDF)
Complete Volume Twenty Two 2022 (PDF)
Complete Volume Twenty One 2021 (PDF)
Complete Volume Twenty 2020 (PDF)
Complete Volume Nineteen 2019 (PDF)
Complete Volume Eighteen 2018 (PDF)
Complete Volume Seventeen 2017 (PDF)